SLS-007 is a Peptide-based Approach Targeting the NACore (nonamyloid component core) for Parkinson’s Disease
- Family of rationally-designed peptide inhibitors that target the aggregation of alpha-synuclein
(α-synuclein) acquired from UCLA
- Pre-clinical data provide supportive evidence to slow progression – an early sign of disease-modifying potential in Parkinson’s disease
- Recent in-vitro and cell culture research have shown the ability to stop the propagation and seeding of α-synuclein aggregates against increased monomeric α-synuclein expression, fibril preparations of seeded α-synuclein, and α-synuclein seeds derived from patients diagnosed with Parkinson's disease or Lewy Body Dementia
- Seelos will evaluate the potential for in-vivo delivery of SLS-007 in a PD transgenic mice model
- The goal will be to establish in-vivo PK/PD and target engagement parameters of SLS-007, a family of anti-alpha-synuclein peptidic inhibitors
- Alpha-synuclein (α-synuclein) is a protein whose function in the healthy brain is currently unknown
- It is of great interest to Parkinson's researchers because it is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of Parkinson's disease
- In the several years since its discovery, α-synuclein has been the focus of intensive efforts by basic Parkinson's disease researchers working to definitively characterize the protein's role in Parkinson's and its potential as a target for neuroprotective therapies
SLS-007: Alpha-synuclein as a Therapeutic Target
- Stoker TB, Torsney KM, Barker RA. Emerging treatment approaches for Parkinson’s Disease. Front Neurosci. 2018; 12:693.
2. Brundin P, Dave KD, Kordower. Therapeutic approaches to target alpha-synuclein pathology. Experimental Neurology. 2017;298:225-235.